Modification on the O-glucoside of Sergliflozin-A: A new strategy for SGLT2 inhibitor design

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.

Y. Kanai, W S Lee, Dennis Brown et al. · Journal of Clinical Investigation · 1994 · 619 citations · Full text

Glycobiology, High Capacity, Cellular Physiology +20

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Wei Meng, Bruce A. Ellsworth, Alexandra A. Nirschl et al. · Journal of Medicinal Chemistry · 2008 · 612 citations · Full text

Metabolic Syndrome, Diabetes Management, Biochemistry +10

Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

Rolf Grempler, Leo Thomas, Matthias Eckhardt et al. · Diabetes Obesity and Metabolism · 2011 · 583 citations

Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

Song‐Ping Han, Deborah Hagan, Joseph R. Taylor et al. · Diabetes · 2008 · 416 citations · Full text

Discovery of Canagliflozin, a Novel <i>C</i>-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

Sumihiro Nomura, Shigeki Sakamaki, Mitsuya Hongu et al. · Journal of Medicinal Chemistry · 2010 · 371 citations · Full text

Heteroaromatic Ring, Metabolic Syndrome, Medicinal Chemistry +15